DK0854867T3 - Tetrahydroquinoliner som NMDA-antagonister - Google Patents
Tetrahydroquinoliner som NMDA-antagonisterInfo
- Publication number
- DK0854867T3 DK0854867T3 DK96933399T DK96933399T DK0854867T3 DK 0854867 T3 DK0854867 T3 DK 0854867T3 DK 96933399 T DK96933399 T DK 96933399T DK 96933399 T DK96933399 T DK 96933399T DK 0854867 T3 DK0854867 T3 DK 0854867T3
- Authority
- DK
- Denmark
- Prior art keywords
- tetrahydroquinolines
- nmda antagonists
- nmda
- antagonists
- Prior art date
Links
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000003530 tetrahydroquinolines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9519893.3A GB9519893D0 (en) | 1995-09-29 | 1995-09-29 | Heterocyclic compounds |
| GBGB9617306.7A GB9617306D0 (en) | 1996-08-17 | 1996-08-17 | Heterocyclic compounds |
| PCT/EP1996/004206 WO1997012870A1 (en) | 1995-09-29 | 1996-09-26 | Tetrahydroquinolines as nmda antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0854867T3 true DK0854867T3 (da) | 2002-12-02 |
Family
ID=26307841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96933399T DK0854867T3 (da) | 1995-09-29 | 1996-09-26 | Tetrahydroquinoliner som NMDA-antagonister |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5977136A (cs) |
| EP (1) | EP0854867B1 (cs) |
| JP (1) | JP4108123B2 (cs) |
| KR (1) | KR100464895B1 (cs) |
| CN (1) | CN1130346C (cs) |
| AP (1) | AP876A (cs) |
| AR (1) | AR005233A1 (cs) |
| AT (1) | ATE221520T1 (cs) |
| AU (1) | AU708148B2 (cs) |
| BR (1) | BR9610733A (cs) |
| CA (1) | CA2232509A1 (cs) |
| CZ (1) | CZ292379B6 (cs) |
| DE (1) | DE69622731T2 (cs) |
| DK (1) | DK0854867T3 (cs) |
| EA (1) | EA000875B1 (cs) |
| ES (1) | ES2180799T3 (cs) |
| HU (1) | HUP9900040A3 (cs) |
| IL (1) | IL123322A0 (cs) |
| IS (1) | IS4677A (cs) |
| MX (1) | MX9801967A (cs) |
| NO (1) | NO310355B1 (cs) |
| NZ (1) | NZ319596A (cs) |
| PL (1) | PL186781B1 (cs) |
| PT (1) | PT854867E (cs) |
| SI (1) | SI0854867T1 (cs) |
| TR (1) | TR199800531T1 (cs) |
| TW (1) | TW460465B (cs) |
| WO (1) | WO1997012870A1 (cs) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9617305D0 (en) * | 1996-08-17 | 1996-09-25 | Glaxo Wellcome Spa | Heterocyclic compounds |
| GB9706294D0 (en) * | 1997-03-26 | 1997-05-14 | Glaxo Wellcome Spa | Heterocyclic compound |
| MY125037A (en) | 1998-06-10 | 2006-07-31 | Glaxo Wellcome Spa | 1,2,3,4 tetrahydroquinoline derivatives |
| TW555757B (en) * | 1998-07-31 | 2003-10-01 | Akzo Nobel Nv | Aminomethylcarboxylic acid derivatives |
| CA2339662A1 (en) * | 1998-08-07 | 2000-02-17 | Takeda Chemical Industries, Ltd. | Benzothiepin derivatives, their production and use |
| GB9929037D0 (en) * | 1999-12-08 | 2000-02-02 | Glaxo Wellcome Spa | Heterocyclic derivatives |
| ATE304533T1 (de) * | 2001-12-28 | 2005-09-15 | Acadia Pharm Inc | Tetrahydrochinolinderivate als muscarinische agonisten |
| DE10236910A1 (de) * | 2002-08-12 | 2004-03-11 | Grünenthal GmbH | Substituierte 1,2,3,4-Tetrahydrochinolinderivate |
| US7910751B2 (en) * | 2005-07-22 | 2011-03-22 | Mochida Pharmaceutical Co., Ltd. | Heterocyclidene acetamide derivative |
| RU2451014C2 (ru) * | 2005-07-22 | 2012-05-20 | Мотида Фармасьютикал Ко., Лтд. | Новое производное гетероциклиден ацетамида |
| AU2009221179A1 (en) | 2008-03-05 | 2009-09-11 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| EP2286808A1 (en) * | 2009-08-18 | 2011-02-23 | Rheinische Friedrich-Wilhelms Universität | Cytohesin inhibitors |
| KR20120123089A (ko) | 2010-02-16 | 2012-11-07 | 화이자 인코포레이티드 | 5-ＨＴ₄ 수용체의 부분 효능제인 (Ｒ)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조［ｄ］이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2Ｈ-피란-4-올 |
| SG183321A1 (en) | 2010-02-19 | 2012-09-27 | Boehringer Ingelheim Int | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| AR087577A1 (es) | 2011-08-17 | 2014-04-03 | Boehringer Ingelheim Int | Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparacion |
| WO2016114655A1 (en) * | 2015-01-12 | 2016-07-21 | Ry Pharma B.V. | Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation |
| WO2017065602A1 (en) * | 2015-10-13 | 2017-04-20 | Ry Pharma B.V. | Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE147732T1 (de) * | 1989-03-08 | 1997-02-15 | Merck Sharp & Dohme | Tetrahydroquinolin-derivate, verwendbar bei neurodegenerativen krankheiten |
-
1996
- 1996-09-26 DE DE69622731T patent/DE69622731T2/de not_active Expired - Lifetime
- 1996-09-26 IL IL12332296A patent/IL123322A0/xx not_active IP Right Cessation
- 1996-09-26 TR TR1998/00531T patent/TR199800531T1/xx unknown
- 1996-09-26 AP APAP/P/1998/001212A patent/AP876A/en active
- 1996-09-26 AU AU72148/96A patent/AU708148B2/en not_active Ceased
- 1996-09-26 KR KR10-1998-0702321A patent/KR100464895B1/ko not_active Expired - Fee Related
- 1996-09-26 CZ CZ1998940A patent/CZ292379B6/cs not_active IP Right Cessation
- 1996-09-26 ES ES96933399T patent/ES2180799T3/es not_active Expired - Lifetime
- 1996-09-26 SI SI9630523T patent/SI0854867T1/xx unknown
- 1996-09-26 PL PL96325966A patent/PL186781B1/pl not_active IP Right Cessation
- 1996-09-26 CA CA002232509A patent/CA2232509A1/en not_active Abandoned
- 1996-09-26 EP EP96933399A patent/EP0854867B1/en not_active Expired - Lifetime
- 1996-09-26 PT PT96933399T patent/PT854867E/pt unknown
- 1996-09-26 CN CN96198560A patent/CN1130346C/zh not_active Expired - Fee Related
- 1996-09-26 DK DK96933399T patent/DK0854867T3/da active
- 1996-09-26 WO PCT/EP1996/004206 patent/WO1997012870A1/en active IP Right Grant
- 1996-09-26 HU HU9900040A patent/HUP9900040A3/hu unknown
- 1996-09-26 BR BR9610733A patent/BR9610733A/pt not_active IP Right Cessation
- 1996-09-26 EA EA199800230A patent/EA000875B1/ru not_active IP Right Cessation
- 1996-09-26 US US09/029,860 patent/US5977136A/en not_active Expired - Fee Related
- 1996-09-26 NZ NZ319596A patent/NZ319596A/en not_active IP Right Cessation
- 1996-09-26 JP JP51394797A patent/JP4108123B2/ja not_active Expired - Fee Related
- 1996-09-26 AT AT96933399T patent/ATE221520T1/de not_active IP Right Cessation
- 1996-09-30 AR ARP960104543A patent/AR005233A1/es active IP Right Grant
- 1996-10-04 TW TW085112168A patent/TW460465B/zh not_active IP Right Cessation
-
1998
- 1998-02-27 IS IS4677A patent/IS4677A/is unknown
- 1998-03-12 MX MX9801967A patent/MX9801967A/es not_active IP Right Cessation
- 1998-03-27 NO NO19981396A patent/NO310355B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69525857D1 (de) | Östrogen-agonisten/antagonisten | |
| EE9600186A (et) | Neurokiniini (tahhüülkiniini) antagonistid | |
| DK1009732T3 (da) | 1-Amino-alkylcyclohexan NMDA receptor antagonister | |
| NO974463D0 (no) | Anordninger for tele-arbeid | |
| FI960516L (fi) | Substituoituja bifenyylisulfonamidiendoteliiniantagonisteja | |
| FI961628A0 (fi) | Indolijohdannaisia NMDA-antagonisteina | |
| DK0854867T3 (da) | Tetrahydroquinoliner som NMDA-antagonister | |
| DK0922034T3 (da) | Tetrahydroquinolinderivater som EAA-antagonister | |
| DK1068202T3 (da) | 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister | |
| NO974043L (no) | Indolderivater som EAA-antagonister | |
| DK0929521T3 (da) | NMDA-antagonister (N-methyl-D-aspartat-antagnonister) | |
| FI972862A7 (fi) | Uudet stafylokinaasijohdannaiset | |
| ATA46395A (de) | Hängebahn | |
| DK0770603T3 (da) | Alkynylphenylaminosulfonylurinstoffer som herbicider | |
| KR970702876A (ko) | 뉴로키닌 길항제(Neurokinine (tachykinine) antagonists) | |
| EE03762B1 (et) | Protsess NMDA antagonistide valmistamiseks | |
| FI970143A0 (fi) | Kinoliinijohdannaiset leukotrieeniantagonisteina | |
| KR950027351U (ko) | 반목 항타장치 | |
| SE9502290D0 (sv) | New Preparation | |
| FI960434A0 (fi) | Slaganordning som arbetar med hydrauliskt tryck | |
| FI940181A0 (fi) | Foerfarande foer aostadkommande av en masspektrometer som fungerar under lufttryck | |
| FIU950183U0 (fi) | Faerdiggraeddad matsporation avsedd att foertaeras som engaongsportion | |
| SK1155U (sk) | Rameno |